Astrazeneca (AZN) Accumulated Expenses (2016 - 2025)

Astrazeneca has reported Accumulated Expenses over the past 11 years, most recently at $7.3 billion for Q4 2025.

For Q4 2025, Accumulated Expenses rose 12.3% year-over-year to $7.3 billion; the TTM value through Dec 2025 reached $7.3 billion, up 12.3%, while the annual FY2025 figure was $7.3 billion, 12.3% up from the prior year.
Accumulated Expenses for Q4 2025 was $7.3 billion at Astrazeneca, up from $6.5 billion in the prior quarter.
Over five years, Accumulated Expenses peaked at $7.3 billion in Q4 2025 and troughed at -$911.0 million in Q1 2021.
A 5-year average of $5.0 billion and a median of $5.9 billion in 2021 define the central range for Accumulated Expenses.
Biggest five-year swings in Accumulated Expenses: soared 44.66% in 2021 and later fell 1.73% in 2022.
Year by year, Accumulated Expenses stood at $5.6 billion in 2021, then fell by 1.73% to $5.6 billion in 2022, then increased by 10.11% to $6.1 billion in 2023, then grew by 5.74% to $6.5 billion in 2024, then grew by 12.3% to $7.3 billion in 2025.
Business Quant data shows Accumulated Expenses for AZN at $7.3 billion in Q4 2025, $6.5 billion in Q4 2024, and $6.1 billion in Q4 2023.

Peer Comparison